Since the company’s inception, Tetraphase has developed a robust antibiotics platform based on the tetracycline core chemical structure, which offers the potential to dramatically improve the treatment of serious bacterial infections. Tetraphase has utilized this fully-synthetic chemistry technology to create a pipeline of novel tetracycline antibiotics, particularly those with activity against the toughest multidrug-resistant Gram-negative bacteria.

$ 8.11 +0.03 (0.37%)
Day High: 8.27
Day Low:  8.01
Volume:    497,228
4:00 PM ET
Mar 24, 2017

Delayed ~20 min., by eSignal.

Press Releases

Events & Presentations

Mar 13, 2017 / 11:00 AM ET